IgG4-related skin disease successfully treated by thalidomide: A report of 2 cases with emphasis on pathological aspects

JAMA Dermatology

Volumn 149, Issue 6, 2013, Pages 742-747

  Ingen Housz Oro, Saskia ^a   Ortonne, Nicolas ^d   Elhai, Muriel ^b   Allanore, Yannick ^b   Aucouturier, Pierre ^c   Chosidow, Olivier ^a,d,e  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL TENON   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; INTERLEUKIN 6; SMAD2 PROTEIN; SMAD3 PROTEIN; THALIDOMIDE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CONSULTATION; DRUG DOSE REDUCTION; DRUG EFFICACY; ERYTHEMA; FIBROSIS; FOLLOW UP; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN G4 RELATED DISEASE; IMMUNOGLOBULIN G4 RELATED SKIN DISEASE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LUPUS VULGARIS; LYMPHOCYTIC INFILTRATION; MALE; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REMISSION; SKIN BIOPSY; SKIN DISEASE; SKIN EXAMINATION; SKIN NODULE;

ADULT; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SKIN DISEASES; T-LYMPHOCYTES, HELPER-INDUCER; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84879389369     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.2625     Document Type: Article

References (26)

1. Ebbo M, Daniel L, Pavic M, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore). 2012;91(1):49-56.
2. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6): 539-551.
3. Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732-738. (Pubitemid 32204991)
4. Kubota T, Moritani S, Katayama M, Terasaki H. Ocular adnexal IgG4-related lymphoplasmacytic infiltrative disorder. Arch Ophthalmol. 2010;128(5):577-584.
5. Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012;64(10):3061-3067.
6. Masaki Y, Kurose N, Yamamoto M, et al. Cutoff values of serum IgG4 and histopathological IgG4- plasma cells for diagnosis of patients with IgG4-related disease. Int J Rheumatol. 2012;2012:580814.
7. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181-1192.
8. Kamisawa T, Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol. 2008;14(25):3948-3955.
9. Zaidan M, Cervera-Pierot P, de Seigneux S, et al. Evidence of follicular T-cell implication in a case of IgG4-related systemic disease with interstitial nephritis. Nephrol Dial Transplant. 2011;26(6):2047-2050.
10. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4- related systemic disease. Arthritis Rheum. 2010;62(6):1755-1762.
11. Cheuk W, Lee KC, Chong LY, Yuen ST, Chan JK. IgG4-related Sclerosing disease: a potential new etiology of cutaneous pseudolymphoma. Am J Surg Pathol. 2009;33(11):1713-1719.
12. Hattori T, Miyanaga T, Tago O, et al. Isolated cutaneous manifestation of IgG4- related disease. J Clin Pathol. 2012;65(9):815-818.
13. Kuo TT, Chen TC, Lee LY, Lu PH. IgG4-positive plasma cells in cutaneous Rosai- Dorfman disease: an additional immunohistochemical feature and possible relationship to IgG4-related sclerosing disease. J Cutan Pathol. 2009;36(10): 1069-1073.
14. Hamaguchi Y, FujimotoM, Matsushita Y, Kitamura-Sawada S, Kawano M, Takehara K. IgG4-related skin disease, a mimic of angiolymphoid hyperplasia with eosinophilia. Dermatology. 2011;223(4):301-305.
15. Benchikhi H, Bodemer C, Fraitag S, et al. Treatment of cutaneous lymphoid hyperplasia with thalidomide: report of two cases. J Am Acad Dermatol. 1999; 40(6, pt 1):1005-1007. (Pubitemid 29268937)
16. Pham-Ledard A, Vergier B, Doutre MS, Beylot-Barry M. Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccination. Dermatology. 2010;220(2):176-179.
17. Gauldie J, Kolb M, Ask K, Martin G, Bonniaud P, Warburton D. Smad3 signaling involved in pulmonary fibrosis and emphysema. Proc Am Thorac Soc. 2006; 3(8):696-702. (Pubitemid 44788227)
18. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum. 2003;48(7):1964-1978. (Pubitemid 36828692)
19. Strehl JD, Hartmann A, Agaimy A. Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol. 2011; 64(3):237-243.
20. Kakudo K, Li Y, Taniguchi E, et al. IgG4-related disease of the thyroid glands. Endocr J. 2012;59(4):273-281.
21. Umehara H, Okazaki K, Masaki Y, et al; Research Program for Intractable Disease by Ministry of Health, Labor and Welfare (MHLW) Japan G4 team. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012;22(1):1-14.
22. Tabata C, Tabata R, Kadokawa Y, et al. Thalidomide prevents bleomycininduced pulmonary fibrosis in mice. J Immunol. 2007;179(1):708-714. (Pubitemid 46986590)
23. Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007;45(6):1538-1546. (Pubitemid 46918338)
24. Kusuda T, Uchida K, Miyoshi H, et al. Involvement of inducible costimulator- and interleukin 10-positive regulatory T cells in the development of IgG4-related autoimmune pancreatitis. Pancreas. 2011;40(7):1120-1130.
25. Tanaka A, Moriyama M, Nakashima H, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation ofMikulicz disease. Arthritis Rheum. 2012;64(1):254-263.
26. Ganeshan K, Bryce PJ. Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF-β. J Immunol. 2012;188(2):594-603.